Common polymorphisms in 5-lipoxygenase and 12-lipoxygenase genes and the risk of incident, sporadic colorectal adenoma

Cancer

Volumn 109, Issue 5, 2007, Pages 849-857

  Gong, Zhihong ^a   Hebert, James R ^b,c   Bostick, Roberd M ^d   Deng, Zonglin ^b,c   Hurley, Thomas G ^b,c   Dixon, Dan A ^b,c   Nitcheva, Daniela ^b,c   Xie, Dawen ^b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c South Carolina Cancer Center   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Case control study; Colorectal adenoma; Genetic polymorphisms; Lipoxygenase pathway

Indexed keywords

ADENINE; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; ARGININE; CYTOSINE; GLUTAMINE; GUANINE; ICOSATETRAENOIC ACID; LEUKOTRIENE; THYMINE;

ADULT; AGED; ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER INCIDENCE; CANCER RISK; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME MECHANISM; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL;

ADENOMA; ADULT; AGED; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 5-LIPOXYGENASE; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 33847405410     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22469     Document Type: Article

References (48)

1. American Cancer Society. Cancer Facts and Figures, 2005. Atlanta, Ga: American Cancer Society; 2005.
2. Parkin DM. Cancer Incidence in Five Continents. Lyon: International Agency for Research on Cancer; 1992.
3. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999;91:916-932.
4. Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R, Das S. Arachidonic acid and colorectal carcinogenesis. Mol Cell Biochem. 2003;253:141-149.
5. Cuendet M, Pezzuto JM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact. 2000;17:109-157.
6. Nie D, Honn KV. Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci. 2002;59:799-807.
7. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871-1875.
8. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002;190:279-286.
9. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 2001;276:18075-18081.
10. Nasir A, Fernandez PM, Chughtai OR, Kaiser HE. COX-2, NSAIDs and human neoplasia. Part I: colorectal neoplasms. In Vivo. 2002;16:501-509.
11. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001;61:6307-6312.
12. Silverman ES, Drazen JM. The biology of 5-lipoxygenase: function, structure, and regulatory mechanisms. Proc Assoc Am Physicians. 1999;111:525-536.
13. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta. 1996;1300:240-246.
14. DuBois RN. Leukotriene A4 signaling, inflammation, and cancer. J Natl Cancer Inst. 2003;95:1028-1029.
15. Chen X, Wang S, Wu N, Yang CS. Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr Cancer Drug Targets. 2004;4:267-283.
16. Hussey HJ, Bibby MC, Tisdale MJ. Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504) against established murine adenocarcinomas (MAC). Br J Cancer. 1996;73:1187-1192.
17. Muller-Peddinghaus R. Potential anti-inflammatory effects of 5-lipoxygenase inhibition-exemplified by the leukotriene synthesis inhibitor BAY X 1005. J Physiol Pharmacol. 1997;48:529-536.
18. Kennedy TJ, Chan CY, Ding XZ, Adrian TE. Lipoxygenase inhibitors for the treatment of pancreatic cancer. Expert Rev Anticancer Ther. 2003;3:525-536.
19. Nie D, Tang K, Diglio C, Honn KV. Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood. 2000;95:2304-2311.
20. Natarajan R, Esworthy R, Bai W, Gu JL, Wilczynski S, Nadler J. Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor. J Clin Endocrinol Metab. 1997;82:1790-1798.
21. Kamitani H, Geller M, Eling T. The possible involvement of 15-lipoxygenase/leukocyte type 12-lipoxygenase in colorectal carcinogenesis. Adv Exp Med Biol. 1999;469:593-598.
22. Nie D, Hillman GG, Geddes T, et al. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res. 1998;58:4047-4051.
23. Chopra H, Timar J, Chen YQ, et al. The lipoxygenase metabolite 12(S)-HETE induces a cytoskeleton-dependent increase in surface expression of integrin alpha IIb beta 3 on melanoma cells. Int J Cancer. 1991;49:774-786.
24. Tang DG, Chen YQ, Honn KV Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA. 1996;93:5241-5246.
25. Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 2002;62:2721-2727.
26. In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 1997;99:1130-1137.
27. Fridman C, Ojopi EP, Gregorio SP, et al. Association of a new polymorphism in ALOX12 gene with bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2003;253:40-43.
28. Huls G, Koornstra JJ, Kleibeuker JH. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet. 2003;362:230-232.
29. Hardman AE. Physical activity and cancer risk. Proc Nutr Soc. 2001;60:107-113.
30. Friedenreich CM. Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev. 2001;10:287-301.
31. Gong Z, Xie D, Deng Z, et al. The PPARγ Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas. Carcinogenesis. 2005;26:579-585.
32. O'Brien MJ, Winawer SJ, Zauber AG, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology. 1990;98:371-379.
33. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122:51-65.
34. Pereira MA, FitzerGerald SJ, Gregg EW, et al. A collection of physical activity questionnaires for health-related research. Med Sci Sports Exerc. 1997;29:S1-205.
35. SAS Institute Inc. SAS Language: Reference, Version 9.1. Cary, NC: SAS Institute; 2004.
36. Khoury MJ, James LM. Population and familial relative risks of disease associated with environmental factors in the presence of gene-environment interaction. Am J Epidemiol. 1993;137:1241-1250.
37. Agresti A. An Introduction to Categorical Data Analysis. New York: John Wiley & Sons, Inc.; 1996.
38. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. 2003;17:1986-1995.
39. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis. 2004;25:2467-2472.
40. Asano TK, McLeod RS. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum. 2004;47:665-673.
41. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 2002;3:166-174.
42. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol. 1996;52:237-245.
43. Slattery ML, Potter JD. Physical activity and colon cancer: confounding or interaction? Med Sci Sports Exerc. 2002;34:913-919.
44. Whelan J, McEntee MF. Dietary (n-6) PUFA and intestinal tumorigenesis. J Nutr. 2004;134:3421S-3426S.
45. Hebert JR, Miller DR. Methodologic considerations for investigating the diet-cancer link. Am J Clin Nutr. 1988;47:1068-1077.
46. Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev. 2006;15:502-508.
47. Hebert JR, Ebbeling CB, Matthews CE, et al. Systematic errors in middle-aged women's estimates of energy intake: comparing three self-report measures to total energy expenditure from doubly labeled water. Ann Epidemiol. 2002;12:577-586.
48. Kipnis V, Midthune D, Freedman LS, et al. Empirical evidence of correlated biases in dietary assessment instruments and its implications. Am J Epidemiol. 2001;153:394-403.